開發進程 Compound Platform Indication Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA Partner Pidnarulex CX-5461 G-quadruplex (stabilizer) 乳癌 (已完成) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 加拿大 Dream team/CCTG Pidnarulex CX-5461 G-quadruplex (stabilizer) 卵巢癌 /乳癌/其他實體腫瘤 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 美國/加拿大 Pidnarulex CX-5461 G-quadruplex (stabilizer) 血液性癌症 (已完成) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 澳洲 PMCC Pidnarulex CX-5461 G-quadruplex (stabilizer) 前列腺癌 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 澳洲 PCF/Pfizer/PMCC Pidnarulex CX-5461 G-quadruplex (stabilizer) 實體腫瘤 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 美國 NCI-NExT Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) 膽管癌 (已完成) Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 美國/韓國/台灣 Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) 基底細胞癌 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 美國 Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) 髓母細胞瘤 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 美國 PBTC/Stanford Univ. Silmitasertib CX-4945 Casein Kinase 2 (inhibitor) 社區型肺炎 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 台灣/美國 Silmitasertib CX-4945 Casein Kinase 2 (inhibitor ) 神經母細胞瘤 Phase 1 Phase 1b/ Expansion Phase 2 Phase 3 NDA 美國 PSU/BCC/Four Diamonds Foundation